Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2021

View Archived Issues

New phase I/II study of bintrafusp alfa with M-9241 and docetaxel in metastatic prostate cancer

Movement strengthens bones, and immunity

Atherosclerosis precedes clonal hematopoiesis

Ascendis initiates phase III trial of TransCon PTH for hypoparathyroidism

PIPE-307 enters phase I development as potential treatment of multiple sclerosis

Cancer-associated fibroblasts influence GIST progression and metastasis through PDGFC secretion

GcgR antagonist enhances functional beta-cell mass and glycemic control in type 1 diabetes

Topline data from BRAVE-AA2 phase III study of baricitinib in severe alopecia areata

MediciNova discontinues development of vaccine for COVID-19

FDA accepts IND application for EP-7041 for thrombosis prevention in patients with COVID-19

Guangdong Xiangxue Life Sciences patents TCRs targeting AFP-derived short peptide

New IRAK-4 inhibitors identified at Bristol Myers Squibb

Alkermes presents new mu-opioid receptor agonists

Ankh Life Sciences describes new anticancer compounds

Xentria submits IND application to the FDA for XTMAB-16 as treatment of sarcoidosis

Arbutus Biopharma identifies HBsAg secretion inhibitors

Wellmarker Bio receives phase I study approval for WM-S1-030 in Australia

Galapagos reports interim data from safety studies of filgotinib

Positive topline data from phase II program of AZR-MD-001 in Meibomian gland dysfunction

PHA-022121 shows promise for treating hereditary angioedema

Benralizumab achieves OCS elimination or reduction in OCS-dependent asthmatics

MiR-939-5p, tumor suppressor and potential therapeutic target in TNBC

FDA clears IND for pilot study of NVD-003 for congenital pseudarthrosis of the tibia

FDA clears initiation of phase I study of DT-2216 for solid tumors

COVID-eVax vaccine enters phase I/II study

CFI-402257 plus paclitaxel shows manageable safety in HER2-negative breast cancer patients

Nuformix reports preclinical data on NXP-002 in combination therapy for IPF

"Confounders" could be bountiful harvest rather than nuisance in epigenomics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.